Lite Strategy, Inc. (LITS) stock
Close on Nov 12, 2026Market cap $27.58MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $27.58M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.49
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$51.49M
- EPS, diluted
- -$1.38
- Book value per share
- $1.71
- Diluted shares
- 33M
Trading
- Previous close
- $0.99
- Open
- $0.96
- Day's range
- $0.90 – $0.96
- Volume
- 258,199
- Average volume (20 days)
- 250,619
- Beta (5 years)
- 0.70
- 52-week range
- $0.69 – $2.15
- RSI (14 days)
- 37.1
- Volatility (1 year)
- 78.2%
- Relative volume
- 0.64×
- WACC
- 8.4%
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | LITS | S&P 500 | Difference | LITS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -25.7% | -2.7% | −23.0 pts | ||
| 3 months | -1.6% | -1.7% | +0.2 pts | ||
| Year to date | -31.3% | +11.9% | −43.2 pts | ||
| 1 year | -54.9% | +12.0% | −66.9 pts | ||
| 3 years | -83.6% | +78.2% | −161.8 pts | -45.3% | +21.2% |
| 5 years | -98.2% | +73.2% | −171.4 pts | -55.1% | +11.6% |
| 10 years | -96.5% | +309.6% | −406.1 pts | -28.4% | +15.1% |
Fifteen years at a glance
Fiscal years 2012 to 2026 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Lite Strategy filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- News
- Update
About Lite Strategy
Finance Services
Lite Strategy, Inc. is a biopharmaceutical company engaged in pre-clinical development programs for non-oncologic disease indications, after historically developing cancer therapies. The company's drug candidate pipeline features voruciclib, an orally administered cyclin-dependent kinase 9 inhibitor, and zandelisib, an oral selective PI3Kδ inhibitor. In addition to pharmaceutical research, the company maintains Litecoin as a primary treasury reserve asset and manages covered call option strategies on its digital asset holdings. Potential customers and commercial partners include biotechnology and pharmaceutical companies, research institutions, and healthcare collaborators targeted for out-licensing, program sales, or clinical development partnerships.
Company profile, executives and historyLite Strategy stock: common questions
What is Lite Strategy's stock price?
LITS closed at $0.91 on Nov 12, 2026, down 7.94% on the day. Over the past 52 weeks it traded between $0.69 and $2.15.
What is Lite Strategy's market cap?
Lite Strategy was worth $27.58M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is LITS's P/E ratio?
Lite Strategy lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.38), so it has no meaningful P/E ratio.
Does Lite Strategy pay a dividend?
No. Lite Strategy has not paid a cash dividend over the last twelve months.
How has LITS stock performed over the past year?
Including dividends, LITS returned -54.9% over the past year, against +12.0% for the S&P 500.
How many LITS shares are sold short?
0M shares were sold short at the latest FINRA report, 0.47% of the float, or 1.0 days of average trading volume.
Who are Lite Strategy's competitors?
Companies most similar to Lite Strategy by business, industry and size include CNTN, TAOX, ENLV, USBC, SDEV.
See a number that looks wrong?